
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom's stock outlook remains positive due to a strong 22% year-over-year growth in international revenue, supported by successful market expansions in France and Canada. The company's domestic revenue also showed robust performance, increasing 21% year-over-year and capturing a larger share of the Type 2 diabetes market, which positions DexCom favorably for future growth. Additionally, management's raised full-year sales guidance, anticipating $4.630B-$4.650B, reflects confidence in the ongoing impact of pipeline innovations and expanded coverage, which are expected to drive significant market penetration and profitability.
Bears say
DexCom is lowering its profitability outlook for the year, reflecting concerns about the company's business quality and the impact of increased competition and integration challenges with insulin pumps. The adjusted EBIT and EBITDA expectations have decreased by 50 basis points to 20%-21% and 29%-30%, while the gross margin forecast has also dropped to 61% due to issues related to scrap rates and sensor quality. Furthermore, management's decision to revise future sales growth forecasts to approximately 12% and 13% for 2026 and 2027 suggests a cautious outlook amid operational challenges and intensifying competition in the continuous glucose monitoring market.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares